TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2011

Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma.

Bert H O'Neil et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.